Synphabase
SynphaBase AG is a Swiss CDRO founded in 2000 that provides custom synthesis of complex carbohydrates, RNA, peptides, and conjugates for pharmaceutical and biotechnology clients. It delivers GMP-grade material for early clinical phases under ISO 9001 and Swissmedic compliance.
- Company typePrivate
- Founded2000
- HeadquartersPratteln, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
Synphabase firmographics
Firmographics- Name
- Synphabase
- Legal name
- SynphaBase AG
- Website
- https://synphabase.ch
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SynphaBase AG is a Swiss CDRO founded in 2000 that provides custom synthesis of complex carbohydrates, RNA, peptides, and conjugates for pharmaceutical and biotechnology clients. It delivers GMP-grade material for early clinical phases under ISO 9001 and Swissmedic compliance.
- Ownership category
- akta.pro rank
Synphabase industry classification
Industry- Product category
- Pharmaceutical Contract Research and Manufacturing Services (CDRO)
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Synphabase is headquartered
LocationHeadquarters
- HQ city
- Pratteln
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Synphabase business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Contract Research & Development Services: Custom synthesis services for complex molecules including route design, process optimization, and development of synthesis strategies for pharmaceutical clients.
- Material Supply: Supply of small-scale quantities from milligram to multi-kilogram scale, including non-GMP and small-scale GMP material for pharmaceutical ingredient production.
- Tech Transfer & Scale-Up Services: Support for technology transfer to external manufacturing partners for large-scale production, enabling clients to scale up from laboratory to commercial production.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Synphabase product offering
Product offeringCore offering
SynphaBase AG is a Swiss Contract Development and Research Organization (CDRO) specializing in bioorganic and glycochemistry. The company delivers custom synthesis of complex molecules across four core product areas: Glycans & Carbohydrate Derivatives, RNA & Nucleotide Building Blocks, Peptides & Amino Acid Derivatives, and Conjugates & Linker Systems, supported by Route Design, Process Optimization, and Material Supply services from milligram to multi-kilogram scale, with GMP manufacturing for early clinical (Phase I/II) supply.
Differentiator
Problem solved
Functional benefit
Products and services
- Glycans & Carbohydrate Derivatives
- RNA & Nucleotide Building Blocks
- Peptides & Amino Acid Derivatives
- Conjugates & Linker Systems
- Route Design Services
- Process Optimization Services
- Material Supply Services
- GMP Manufacturing for Early Clinical Supply
Quantifiable outcome
- Over 2,000 successful projects completed since founding
Companies that use Synphabase
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Synphabase technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Synphabase partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IntravacccoreNon-exclusive strategic partnership combining SynphaBase's expertise in synthetic oligosaccharides and glycochemistry with Intravacc's capabilities in conjugation process development and GMP-compliant manufacturing. The partnership offers vaccine developers an integrated pathway from oligosaccharide procurement through clinical production. Under the agreement, SynphaBase promotes Intravacc as a preferred CDMO for conjugate vaccine services, while Intravacc promotes SynphaBase as a preferred supplier for synthetic oligosaccharides, creating bidirectional preferred partner status for conjugate vaccine programs.
Scale indicators3 records
Synphabase competitors and assessment
Company assessmentBroad incumbents
- Bachem: Swiss-based publicly listed CDMO specializing in peptide and oligonucleotide APIs. Overlaps with SynphaBase on peptide, RNA/nucleotide, and conjugate chemistry but operates at significantly larger scale across a broader portfolio.
- PolyPeptide Group: Swiss peptide and oligonucleotide manufacturer serving global pharma. Comparable on peptide synthesis and GMP supply, though at much larger scale and broader scope than SynphaBase's glycochemistry focus.
- Asymchem: China-headquartered CDMO providing custom synthesis and GMP manufacturing for small molecule APIs. Comparable service model (contract research, route design, scale-up) but at much larger scale and broader chemistry scope than SynphaBase.
- Lonza Group: Swiss-headquartered global CDMO offering small molecule, biologic, and cell/gene therapy services. Overlaps with SynphaBase on custom synthesis and GMP API supply but at vastly larger scale and broader portfolio.
- Corden Pharma (CordenPharma): Global CDMO offering custom synthesis, API manufacturing, and drug product services. Comparable as a CDMO serving pharma innovators with route design and GMP supply, though broader in scope than SynphaBase's glycochemistry focus.
Emerging players
- GlycoVaxyn: Biotech developing bioconjugate vaccines using engineered glycochemistry. Adjacent player in the conjugate vaccine space that intersects SynphaBase's customer base and could be both a customer and a competitor for vaccine antigens.
Direct peers
- Carbogen Amcis: Swiss CDMO specializing in complex API development and manufacturing, including carbohydrate and high-potency chemistry. Highly comparable as a Swiss-headquartered CDMO serving pharma innovators with custom synthesis and GMP supply.
- Dextra Laboratories: UK-based specialist in carbohydrate synthesis and glycoconjugate chemistry for pharma and research customers. Direct niche competitor to SynphaBase in synthetic oligosaccharides and glycochemistry CDMO services.
- Sussex Research Laboratories: Canada-based specialist in complex carbohydrate synthesis and glycoconjugate chemistry. Direct peer serving pharma with custom synthesis of oligosaccharides and carbohydrate derivatives, comparable niche focus to SynphaBase.
Regional players
- Sci-tech Group / GlycoSyn (Callaghan Innovation): New Zealand-based GlycoSyn service offering custom carbohydrate synthesis for research and pharma. Direct niche peer in synthetic glycochemistry CDMO services but serving primarily Asia-Pacific customers.
Market position
Customer concentration
Synphabase social profiles
Digital presenceSynphabase compliance and trust
Trust signalCompliance2 records
Synphabase financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synphabase leadership team
Management profileNumber of profiles
Profiles2 records
Synphabase funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synphabase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synphabase
What does Synphabase do?
SynphaBase AG is a Swiss Contract Development and Research Organization (CDRO) specializing in bioorganic and glycochemistry. The company delivers custom synthesis of complex molecules across four core product areas: Glycans & Carbohydrate Derivatives, RNA & Nucleotide Building Blocks, Peptides & Amino Acid Derivatives, and Conjugates & Linker Systems, supported by Route Design, Process Optimization, and Material Supply services from milligram to multi-kilogram scale, with GMP manufacturing for early clinical (Phase I/II) supply.
Is Synphabase a public or private company?
Synphabase is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Synphabase founded?
Synphabase was founded in 2000. It employs 11 to 50 people.
Where is Synphabase based?
Synphabase is headquartered in Pratteln, Switzerland, in the Europe region.
How does Synphabase make money?
Three revenue lines are on record. Contract Research & Development Services are the primary driver. The others are material Supply and tech Transfer & Scale-Up Services.
Who are Synphabase's main competitors?
Broad incumbents on record are Bachem, PolyPeptide Group, Asymchem, Lonza Group and Corden Pharma (CordenPharma). GlycoVaxyn is listed as an emerging player. Direct peers are Carbogen Amcis, Dextra Laboratories and Sussex Research Laboratories. Sci-tech Group / GlycoSyn (Callaghan Innovation) is listed as a regional player.
Does Synphabase have an API?
No public API is recorded for Synphabase.
What industry is Synphabase in?
Synphabase's product category is Pharmaceutical Contract Research and Manufacturing Services (CDRO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 5417 and its SIC code is 8731.